Hybrid, device-enabled IPF cough trial for a Swedish sponsor— integrated formulation-to-site execution by Syngene
In this case study, you would learn how Syngene enabled a hybrid, device-based IPF cough trial in India for a clinical-stage pharma company—delivering seamless formulation-to-site execution with robust data integrity, regulatory navigation, and on-time delivery.
How to choose a CRDMO at CPHI Frankfurt 2025: A Fieldguide
CPHI Frankfurt 2025 is the year’s most efficient place to compare science, scale, and reliability in one hall. Sponsors meet teams, see facilities represented across regions, and validate claims in real time.
Syngene Enables Orocidin to Achieve Clinically Acceptable Antimicrobial Peptide
OROCIDIN A/S, a company focused on developing a novel treatment for advanced gum disease, or aggressive periodontitis, partnered with Syngene for the synthesis of their lead molecule
Advancing mAb manufacturing with customer-centric solutions
Monoclonal antibodies (mAbs) are lab-engineered proteins that mimic the ability of the immune system to neutralize harmful pathogens. Produced by identical immune cells cloned from a single parent cell, these antibodies target a specific antigen with high precision. Their applications span across medicine, treating cancers, autoimmune disorders, and infectious diseases, as well as diagnostics and research.
Rise of the Indian CRO-CDMO: From Cost Arbitrage to Innovation Leadership
From ‘Pharmacy of the World’ to becoming the preferred outsourcing destination for innovative scientific solutions, India’s Life Science industry has seen a dramatic shift. Driving this change is the contract research development manufacturing organization (CRDMO) industry, which witnessed a CAGR of 15% between 2019 and 24, double the global growth rate of 7%–8%.
DMPK Unravelled: Breaking barriers in drug discovery
Time has always been the most serious concern in drug discovery, making it a race¾ not just to develop new treatments but also to deliver safe and effective medicines to patients more quickly.
When Medicines Meet Sunlight: The Rise of In Silico Phototoxicity Testing
One of the less obvious risks in drug development is not how a medicine works inside the body, but how it behaves in the real world, particularly when exposed to sunlight.
Syngene partners with a client for Global Economy Decarbonization
Renewable energy sources are powerful energy alternatives that can tackle climate change challenges and fossil fuel depletion. The Performance & Specialty Materials (PSM) team at Syngene aimed to develop innovative materials for a customer advancing in clean energy solutions such as green hydrogen. This project contributes to global decarbonization efforts by addressing the challenges in […]
Enhancing Patient Compliance: Developing an ExtendedRelease Anti-Epileptic Drug
The current immediate-release (IR) tablet formulation for epilepsy1 , available in Europe, requires multiple doses due to the drug’s short half-life, making it inconvenient for patients. This case study explores the development of an extended-release (ER) formulation by Syngene’s Formulation Development team for an anti-epileptic drug, aimed at reducing the need for frequent dosing and […]
Syngene Enhances Bispecific Antibody Production
The GEM-DIMER™ platform is a proprietary technology developed by Hinge Bio. This technology allows the production of antibodies with enhanced multivalency and multispecificity, enabling the simultaneous targeting of multiple diseaseassociated antigens